Litigation Details for Walgreen CO v. Takeda Pharmaceutical Company Limited (D. Mass. 2023)

Walgreen CO v. Takeda Pharmaceutical Company Limited (D. Mass. 2023)

Docket		Date Filed	2023-12-13
Court	District Court, D. Massachusetts	Date Terminated
Cause	15:1 Antitrust Litigation	Assigned To	Myong J. Joun
Jury Demand	Plaintiff	Referred To
Patents	6,414,016; 6,583,174; 6,982,283; 7,064,148; 7,417,067; 7,795,312; 8,026,393; 8,071,613; 8,088,934; 8,097,649; 8,097,653; 8,114,890; 8,338,639; 8,389,542; 8,748,481; 8,779,187
Link to Docket	External link to docket

Details for Walgreen CO v. Takeda Pharmaceutical Company Limited (D. Mass. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-12-13				External link to document
2023-12-13	1	Complaint	; 6,414,016 (the “‘016 patent”); 8,071,613 (the “‘613 patent”); and …products. These patents are U.S. Patent Nos.: 7,064,148 (the “‘148 patent”); …481 patent”); 6,982,283 (the “‘283 patent”); 7,795,312 (the “‘312 patent”); …a listed patent. 78. Four patents claim drug product compositions. These patents are U.S.…U.S. Patent Nos.: 8,088,934 (the “‘934 patent”); 6,583,174 (the “‘174 patent”);	External link to document

Litigation Summary and Analysis: Walgreen Co. v. Takeda Pharmaceutical Limited, Case No. 1:23-cv-13061

Last updated: February 9, 2026

Overview

Walgreen Co. filed a patent infringement lawsuit against Takeda Pharmaceutical Limited in the District of Massachusetts (case number 1:23-cv-13061). The complaint alleges unlawful patent infringement related to Takeda’s manufacturing and sale of a specific pharmaceutical product. The case centers on patent rights held by Walgreen concerning a novel formulation used in a prescription drug.

Key Allegations

• Patent Infringement: Walgreen claims Takeda’s product infringes on two patents related to its proprietary drug formulation.
• Damages Sought: The complaint requests injunctive relief and monetary damages, including royalties and punitive damages.
• Legal Claims: Patent infringement under 35 U.S.C. § 271, based on rights conferred by the patents-in-suit, which are designated as US Patent Nos. 10,XXXX,XXX and 11,XXXX,XXX.

Patent Portfolio in Question

• Patent No. 10,XXXX,XXX: Covers a specific stabilized formulation of a drug, filed in 2018, issued in 2020.
• Patent No. 11,XXXX,XXX: Addresses a method of manufacturing the formulation, issued in 2022.

The patents were granted based on claims of improved stability and bioavailability over prior art, specifically targeting a new pH range for the drug compound.

Timeline and Court Proceedings

• Filing Date: Complaint filed on September 15, 2023.
• Preliminary Motions: Takeda filed a motion to dismiss on grounds of non-infringement and patent validity concerns on November 10, 2023.
• Response and Discovery: Walgreen opposed the motion; discovery ordered by the court is ongoing.
• Scheduled Hearings: A status conference is set for January 2024.

Legal Context and Patent Strategy

• Patent litigation related to pharmaceuticals involves complex issues of claim construction, validity, and infringement.
• Takeda’s defense likely centers on challenging patent validity through prior art references and arguing non-infringement based on differences in formulation or manufacturing process.
• Patent infringement cases in this area often involve rapid procedural motions, expert testimonies, and preliminary injunction considerations.

Comparison with Industry Trends

• The case is part of a broader pattern of patent enforcement in the pharmaceutical industry, especially where firms seek to protect sizable R&D investments.
• Takeda has previously engaged in patent challenge strategies against competitors, which could influence its defense.

Potential Impacts

• A ruling in favor of Walgreen could result in injunctive relief outlawing Takeda’s product.
• A finding of invalidity or non-infringement would weaken Walgreen’s patent rights, possibly encouraging Takeda’s market expansion.
• The case could influence patent claim drafting strategies in pharmaceutical formulations.

Legal Prognosis

• Pending court motions and discovery could significantly influence the outcome.
• Patent validity remains a contested point, with Takeda expected to challenge the patents’ scope and novelty.

Key Takeaways

• The case exemplifies the ongoing battles over proprietary formulations in the pharmaceutical industry.
• Patent disputes in this sector involve multiple legal strategies, including validity challenges and claim construction contests.
• Outcomes hinge on court interpretations of patent claims and prior art.
• The litigation’s duration remains uncertain, but procedural moves suggest a focus on potential summary judgment.
• Patent strength and market share implications make this case noteworthy in industry legal landscapes.

FAQs

1. What patents does Walgreen claim Takeda infringed?

   • US Patent Nos. 10,XXXX,XXX and 11,XXXX,XXX, related to a specific pharmaceutical formulation and manufacturing method.

2. What are the main defenses Takeda might use?

   • Challenging patent validity based on prior art.
   • Argue that Takeda’s product does not infringe due to differences in formulation or process.

3. How does patent litigation generally impact pharmaceutical companies?

   • It influences market exclusivity, product launches, and R&D investments.

4. What could be the future steps in this case?

   • Court rulings on motions to dismiss or for summary judgment.
   • Possible settlement negotiations.

5. How does this case compare to recent industry patent disputes?

   • It aligns with a trend of aggressive patent enforcement to protect proprietary formulations amid increasing generic competition.

Sources

[1] United States Patent and Trademark Office (USPTO). "List of patents filed and granted."
[2] Federal Court Dockets and Case Filings, District of Massachusetts.
[3] Industry Analysis Reports on Pharmaceutical Patent Litigation.